David C. Sachs - 01 Sep 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role: Chief Financial Officer
Signature: /s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol: IBRX
Transactions as of: 01 Sep 2023
Net transactions value: $0
Form type: 4
Filing time: 06 Sep 2023, 19:41:07 UTC
Previous filing: 28 Aug 2023
Next filing: 03 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IBRX	Common Stock	Options Exercise	$0	+70,744	+138%	$0.000000	122,042	01 Sep 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IBRX	Restricted Stock Units	Options Exercise	$0	-70,744	-50%	$0.000000	70,745	01 Sep 2023	Common Stock	70,744		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2	Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the shares subject to the RSU award vested on September 1, 2023 and 70,745 of the shares shall vest on January 31, 2024.